Bayer claims another win on its CKD and diabetes hopeful, though the question remains over just how big it is
After earning priority review for a top CKD and diabetes program back in January, Bayer is revealing more data that it hopes will boost …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
